Latest News

Our latest progress from the wet labs. Prediction from our AI+QQ in-silico predicted process showing actual in vitro potentiation effect against specific human apoptotic protease. 

We are excited to have been selected to present our OIRD countermeasure results at the NIH/NIDA/BARDA conference.

Prediction from our AI+QQ in-silico predicted process showing actual in vitro inhibition effect against yet another human protease. 

More results from the wet labs -- here our AI+QQ in-silico process is predicting the actual in vitro effect potentiation against an ion channel (our first foray into a CNS indication).

ARIScience presented confirmations of multiple in vitro protease and ion channel inhibition candidates as evidence of progress with our AI+QQ Methodology.

A recent outcome from our wet lab experiments.  Prediction from our AI+QQ in-silico process showing actual in vitro effect (green, blue, purple) against a specific human protease. 

The paper resulting from the "New COVID-19 Variants - Post Challenge Analysis" challenge was accepted and will soon be published by the Cambridge University Press Journal of Clinical and Translational Science

ARIScience continues engage in groundbreaking work on Dengue protein interruption

ARIScience's research on COVID-19's impact on diabetic patients reveals statistically significant associations between metformin use and less severe outcomes from COVID-19 compared to SU use, but not compared to DPP4i use.

ARIScience and University of North Dakota signed a research collaboration agreement on the use of the UND Computational Research Center’s (UND CRC) high performance computing (HPC) system to further ARIScience’s SARS-CoV-2 protein interruption research.

ARIScience recognized by BARDA in pediatric COVID-19 severity prediction AI challenge.

M2D2 selects ARIScience as a "Runner Up" in their 2022 challenge focused on identifying and rewarding disruptive companies in the medical technology and biotechnology industries.

Bridges helps identify meds for other conditions that associate with lower death rates in COVID-19 patients

COVID-19 HPC Consortium and XSEDE provides access to multiple super-computing centers to speed along ARI's breakthrough COVID-19 research.

EHR data from the N3C Data Enclave were used to produce a recent preprint published in medRxiv authored by ARIScience's Joy Alamgir, et al.

Oliver Peckham of HPCWire writes about ARIScience's COVID-19 research results - on the four re-positioned candidate drugs - here.

From early May 2020 we dove right into finding a solution for COVID-19 crisis using our cutting edge quasi-quantum analysis and simulation platform. Our detailed findings are here.

The ongoing rollout of vaccines against COVID-19 has sparked hope of life soon getting back to normal. But vaccines are not the only piece of the pandemic’s jigsaw puzzle. We also need new drugs to fight the disease.

ARIScience now has access to over 1.5MM detailed de-identified patient records (medications, procedures, diagnoses and much more) for COVID-19 research. A video interview of how we are using this dataset can be found here.

In the face of the COVID 19 pandemic, a Massachusetts biotech startup turns to the MGHPCC for HPC resources in its hunt for existing FDA-approved drugs that might be a therapeutic candidate against the novel coronavirus.